title: Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation.
abstract: This is a retrospective analysis of 89 patients who were undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in the Fertility Management Unit of the Department of Obstetrics, Gynaecology and Child Health, The University of the West Indies. Twenty-eight patients (Group A), who did not receive oral contraceptive pills prior to controlled ovarian hyperstimulation (COH) were compared with 61 patients in Group B treated with oral contraceptive pills for two months prior to undergoing COH assisted reproduction using the long protocol. The number of follicles, oocytes, estimated oestradiol levels on the day of administration of human chorionic gonadotrophin (hCG), pregnancy rates, miscarriage rates and the incidence of patients who developed ovarian hyperstimulation syndrome (OHSS) were the main outcome measures. The mean age and haematocrit were the same in each group. The number of follicles retrieved tended to be higher in Group A than in Group B (median 8 versus 6, p = 0.06) with significantly more oocytes being retrieved in Group A than Group B (p < 0.05). There were no statistically significant differences between the two groups in oestradiol levels, the proportion of patients with polycystic ovarian disease, the proportion of women who developed ovarian hyper-stimulation syndrome or pregnancy outcomes. There was no difference between the groups in measures of clinical severity of OHSS. In a logistic regression model the significant predictors of OHSS were haematocrit and oestradiol levels. There appeared to be no significant clinical benefit in administering oral contraceptive pills for two months to patients prior to COH.
authors.affiliation: Fertility Management Unit, Department of Obstetrics, Gynaecology and Child Health, Tropical Metabolism Research Unit, University of the West Indies, Kingston 7, Jamaica, West Indies. jfrederick@jamweb.net
authors.forename: J
authors.initials: J
authors.lastname: Frederick
authors.forename: V
authors.initials: V
authors.lastname: DaCosta
authors.forename: S
authors.initials: S
authors.lastname: Wynter
authors.forename: M
authors.initials: M
authors.lastname: Reid
authors.forename: C
authors.initials: C
authors.lastname: Frederick
authors.forename: C
authors.initials: C
authors.lastname: McKenzie
mesh_terms: D000328:Adult; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use*; D004624:Embryo Transfer; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy*; D008596:Menotropins / Q000009:adverse effects / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000009:adverse effects* / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003278:Contraceptives, Oral, Hormonal; D005300:Fertility Agents, Female; D008596:Menotropins